Data gathered: October 27
AI Stock Analysis - C4 Therapeutics (CCCC)
Analysis generated October 26, 2025. Powered by Chat GPT.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of diseases by harnessing the body's natural protein degradation system. The company's proprietary technology, called TORPEDO (Targeted and Orchestrated Protein Eradication), has the potential to selectively degrade disease-causing proteins, offering a novel mechanism of action distinct from traditional small molecules and antibodies. This innovative approach aims to address a broad range of diseases, including cancer and neurodegenerative conditions.
Stock Alerts - C4 Therapeutics (CCCC)
 |
C4 Therapeutics | October 22 Price is down by -8.5% in the last 24h. |
|
C4 Therapeutics | October 20 Price is up by 6.1% in the last 24h. |
|
C4 Therapeutics | October 17 Price is down by -6.1% in the last 24h. |
|
C4 Therapeutics | October 16 Price is up by 6.5% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for C4 Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 2 | Sign up | Sign up | Sign up |
| Sentiment | 50 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,000 | Sign up | Sign up | Sign up |
| Employee Rating | 88 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | 48 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 23 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,333 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,833 | Sign up | Sign up | Sign up |
| Twitter Mentions | 22 | Sign up | Sign up | Sign up |
| X Mentions | 15 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 63 | Sign up | Sign up | Sign up |
| Linkedin Employees | 119 | Sign up | Sign up | Sign up |
About C4 Therapeutics
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases.
| Price | $2.45 |
| Target Price | Sign up |
| Volume | 1,810,000 |
| Market Cap | $228M |
| Year Range | $1.1 - $3.57 |
| Dividend Yield | 0% |
| Analyst Rating | 71% buy |
| Industry | Biotechnology |
In the news
C4 Therapeutics Announces Pricing of $125 Million Underwritten OfferingOctober 16 - GlobeNewswire |
|
 |
C4 Therapeutics announces trial collab, supply agreement with PfizerOctober 1 - Thefly.com |
 |
C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Average Rating of “Moderate Buy” from AnalystsSeptember 29 - ETF Daily News |
 |
C4 Therapeutics, Inc. (CCCC) Presents at IMS Annual Meeting 2025 Oral Presentation - SlideshowSeptember 24 - SeekingAlpha |
|
C4 Therapeutics (NASDAQ:CCCC) Receives Overweight Rating from StephensSeptember 23 - ETF Daily News |
 |
C4 Therapeutics price target raised by $5 at Wells Fargo, here's whySeptember 23 - Thefly.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '25 | 6.5M | 0 | 6.5M | -26M | -29M | -0.370 |
| Q1 '25 | 7.2M | 2M | 7.2M | -26M | -29M | -0.370 |
| Q4 '24 | 5.2M | 1.8M | 3.4M | -35M | -33M | -0.490 |
| Q3 '24 | 15M | 2.1M | 13M | -25M | -23M | -0.350 |
| Q2 '24 | 12M | 2M | 10M | -18M | -16M | -0.260 |
Insider Transactions View All
| Boyle Scott N filed to sell 107,805 shares at $3.2. February 18 '25 |
| Boyle Scott N filed to sell 110,842 shares at $3.2. February 18 '25 |
| Koppikar Utpal filed to buy 5,667 shares at $5.6. February 10 '23 |
| Hirsch Andrew filed to buy 10,000 shares at $8.4. April 12 '22 |
| Crystal Adam filed to sell 15,000 shares at $32.7. January 5 '22 |
Similar companies
Read more about C4 Therapeutics (CCCC) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of C4 Therapeutics?
The Market Cap of C4 Therapeutics is $228M.
What is the current stock price of C4 Therapeutics?
Currently, the price of one share of C4 Therapeutics stock is $2.45.
How can I analyze the CCCC stock price chart for investment decisions?
The CCCC stock price chart above provides a comprehensive visual representation of C4 Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling C4 Therapeutics shares. Our platform offers an up-to-date CCCC stock price chart, along with technical data analysis and alternative data insights.
Does CCCC offer dividends to its shareholders?
As of our latest update, C4 Therapeutics (CCCC) does not offer dividends to its shareholders. Investors interested in C4 Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of C4 Therapeutics?
Some of the similar stocks of C4 Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.
